Medlive Technology Co., Ltd. (HK:2192) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medlive Technology Co., Ltd. has extended its collaboration with M3 to provide digital market research and content services until the end of 2027. This agreement, originally set to expire in 2024, allows Medlive to continue offering specialized digital surveys and tailored content for medical professionals. The transaction is considered a continuing connected transaction under Hong Kong’s listing rules, requiring certain disclosures but not independent shareholder approval.
For further insights into HK:2192 stock, check out TipRanks’ Stock Analysis page.